US equities |
MU $953.19 ▼-3.62% NVDA $228.52 ▲+0.97% META $762.50 ▲+2.63% AAPL $341.27 ▲+0.09% MSFT $543.45 ▲+0.43% SNDK $1,482.33 ▼-0.34% AMD $605.53 ▲+1.90% SPCX $156.54 ▼-4.21%
FinancialContent

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

4.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inozyme Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
6 Analysts Have This to Say About Inozyme Pharma ↗
 
Via Benzinga
News headline image
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders ↗
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with 
Via Benzinga
News headline image
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) 
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Inozyme Pharma's Future ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Inozyme Pharma ↗
 
Via Benzinga
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Inozyme Pharma ↗
 
Via Benzinga
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701 ↗
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Present at the Jefferies Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Recap: Inozyme Pharma Q1 Earnings ↗
Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated... 
Via Benzinga
News headline image
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
From Inozyme Pharma Inc.
Via GlobeNewswire
News headline image
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Inozyme Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >